The Board of BioProgress plc (AIM: BPRG; NASDAQ: BPRG), the provider of innovative delivery mechanisms for the pharmaceutical and medical device markets, is pleased to announce that it has entered into an agreement to acquire the whole issued share capital of Dexo S.A. (“Dexo”), a French speciality pharmaceutical company. This acquisition, through a newly formed vehicle Dexo BioPharm Ltd (“Dexo BioPharm”), signals a significant change from a drug delivery and material sciences company into an integrated speciality pharmaceutical and healthcare business, which can develop and market its core technologies in combination with other innovative products.
